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Abstract
We aimed to achieve a higher typing resolution within the three dominant Clostridium difficile
ribotypes (591,106 and 002) circulating in Colombia. A total of 50 C. difficile isolates we had
previously typed by PCR-ribotyping, representing the major three ribotypes circulating in
Colombia, were analyzed. Twenty-seven isolates of ribotype 591, 12 of ribotype 106 and 11
of ribotype 002 were subtyped by multiple locus variable-number tandem-repeat analysis
(MLVA). The presence of the PaLoc genes (tcdA/tcdB), toxin production in culture and anti-
microbial susceptibility were also determined. From the total C. difficile ribotypes analyzed,
20 isolates (74%) of ribotype 591, nine (75%) of ribotype 106 and five (45.5%) of ribotype
002 were recovered from patients with Clostridium difficile infection (CDI). MLVA allowed us
to recognize four and two different clonal complexes for ribotypes 591 and 002, respectively,
having a summed tandem-repeat difference (STRD) <2, whereas none of the ribotype 106
isolates were grouped in a cluster or clonal complex having a STRD >10. Six ribotype 591
and three ribotype 002 isolates belonging to a defined clonal complex were isolated on the
same week in two different hospitals. All ribotypes harbored either tcdA+/tcdB+ or tcdA-/
tcdB+ PaLoc genes. Moreover, 94% of the isolates were positive for toxin in culture. All iso-
lates were susceptible to vancomycin and metronidazole, while 75% to 100% of the isolates
were resistant to clindamycin, and less than 14.8% of ribotype 591 isolates were resistant to
moxifloxacina. No significant differences were found among ribotypes with respect to demo-
graphic and clinical patients’ data; however, our results demonstrated a high molecular het-
erogeneity of C. difficile strains circulating in Colombia.
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Introduction
Clostridium difficile infection (CDI) is considered the major cause of infectious diarrhea in
healthcare environments [1]. This infection is associated with the development of mild diar-
rhea to pseudomembranous colitis and toxic megacolon [2]. The incidence and severity of this
bacterial disease have increased worldwide in the last years due to the spreading of the hyper-
virulent and epidemic strain known as PCR ribotype 027 [3,4]. Nonetheless, several studies
have demonstrated the change on the epidemiology of C. difficile in Europe and North Amer-
ica; thus, ribotypes 014/020, 014, 001, 001/072 and 078 are currently more prevalent than ribo-
type 027 [1,5].
In Latin America, the presence of the virulent strain 027 has also been reported in Mexico,
Costa Rica, Panama and Chile [6–9]. Recently in Colombia, C. difficile ribotype 027 was docu-
mented in three CDI patients using the commercial assay Xpert1 C. difficile [10]. Further-
more, a previous study applying the PCR-ribotyping technique to 143 isolates obtained at
three high-complexity hospitals of Medellı´n, Colombia demonstrated the presence of 37 differ-
ent ribotypes the most frequent ones being 591, 106 and 002. Notably, only one isolate corre-
sponded to ribotype 027 and four new ribotypes (795, 795, 804 and 805) were reported [11].
PCR-ribotyping which amplifies the polymorphic sequences in the 16S-23S intergenic
spacer regions (ISR), is the most frequently employed molecular method for the global analysis
of related C. difficile strains, including the epidemic clone; it is also considered the gold stan-
dard method for C. difficile typing [12–14]. However, this technique has lower discriminatory
power, and by itself, is not appropriate to investigate cases of cross infection or to determine
the source of epidemic outbreaks; thus, it is of limited utility in epidemiological studies
[15,16]. Other methods used for typing C. difficile include pulsed-field gel electrophoresis
(PFGE), which has low discriminatory power and restriction endonuclease analysis (REA),
which shows a high discriminatory power, but they can sometimes be difficult to interpret a
times [16]. Although multilocus variable-number tandem-repeat analysis (MLVA) is not as
discriminatory as whole genome sequencing, this subtyping technique is useful for tracking
bacterial transmission at a local level, especially in the case of C. difficile infections [17–19].
Therefore, in this study we evaluated the epidemiological significance of the clustering
obtained by MLVA subtyping of the three major C. difficile Colombian ribotypes (591, 106
and 002).
Material and methods
Study design
This study was conducted between January 2013 and January of 2015 as a part of a cross-sec-
tional study performed in three tertiary care hospitals (denoted by A, B and C) in Medellı´n,
Colombia. C. difficile from patients with suspicion of CDI were isolated by culture and charac-
terized by PCR ribotyping as previously described [20].
Demographic and clinical data
A CDI case was defined if a patient had symptoms that included diarrhea and a stool positive
for C. difficile A/B toxins [11,21]. A review of each patient’s medical record was performed in
order to obtain and collect demographic (age, gender) and clinical data. Data from patients
with other ribotypes were used to compare with equivalent data for patients with ribotypes
591, 106 and 002.
Subtyping C. difficile Colombian isolates by MLVA
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Clostridiumdifficile strains
A total of 50 C. difficile strains that had previously been typed by PCR ribotyping were
included in this study. All the isolates representing the major three ribotypes circulating in
Colombia, as reported in a previous study [11], were selected. The major ribotypes were 591
(n = 27), 106 (n = 12) and 002 (n = 11). C. difficile was grown in brain-heart infusion (BHI)
broth (Becton Dickinson, Franklin Lakes, NJ, USA), and its DNA was extracted using a DNA
isolation kit (MoBio Laboratories Inc., Carlsbad, CA), following the manufacturers’
instructions.
Molecular and phenotypic characterization of C. difficile strains
All C. difficile ribotypes (591, 106 and 002) analyzed in this study were further investigated by
the presence of the toxin genes tcdA and tcdB using standardized methods [21]. The tcdA
(toxin A) and tcdB (toxin B) genes were determined using the NK2/NK3 and NK104/NK105
primers, respectively, to amplify a 375-bp fragment for tcdA and a 203-bp fragment for tcdB
[22]. Toxin production by C. difficile in culture was determined using a standardized cytotoxic
assay [23]. Antimicrobial susceptibility to metronidazole, vancomycin, clindamycin and moxi-
floxacin was determined following guidelines by the Clinical and Laboratory Standards Insti-
tute (CLSI; Document M100-S23) [24]. Bacillus fragilis ATCC 25285 and C. difficile ATCC
500057 were used as resistant and susceptible control strains, respectively.
Multiple-Locus Variable Tandem Repeats analysis (MLVA)
MLVA was performed for the identification of clonally related isolates within each ribotype.
Seven regions within the C. difficile genome with tandem repeat loci were designated and
amplified individually by PCR with specific primers A6, B7, C6, E7, F3, G8, and H9 as previ-
ously described [17–19,21], and using a single protocol [25]. Each forward primer, for all loci,
was labeled with fluorescent dye at the 5’ end with either 6 carboxyfluorescein (FAM), hexa-
chlorofluorescein (HEX), 2’-chloro-7’-phenyl-1,4-dichloro-6-carboxyfluorescein (VIC), or 2’-
chloro-5’-fluoro-7’,8’-fused phenyl-1, 4-dichloro-6 carboxyfluorescein (NED) [25,26]. The
PCR amplification conditions were adjusted for PCR ribotype 078 to improve amplification,
because locus A6 is usually not present in isolates of this ribotype [26]. PCR products were
analyzed using an ABI-PRIMS 3130xl automated sequencer and fragment analysis system
(Life Technologies Ltd, Paisley, UK) with GeneScan 600 LIZ (Applied Biosystems, Life Tech-
nologies, Grand Island, NY) as an internal marker. Fragment sizes were determined with the
GeneMapper v.4.0 software (Applied Biosystems). Repeat numbers were analyzed using Bio-
Numerics software (Applied Maths, Kortrijk, Belgium). The summed absolute distance
between two MLVA-typed isolates is the summed tandem-repeat difference (STRD) at all
seven variable numbers of tandem-repeat (VNTR) loci.
To identify clustering among C. difficile isolates, we determined the number of differences
in tandem repeats increases; thus, isolates differing by 0, 1, or 2 tandem repeats (STRD2)
were considered clonal complexes or indistinguishable, while those isolates that differed by
up to 10 tandem repeats (STRD 10) were considered as genetically related [19,25]. The
Subtyping C. difficile Colombian isolates by MLVA
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epidemiological significance of the clustering among CDI cases was further evaluated by add-
ing the variables time and space in the analysis.
Statistical analysis
Statistical analyses were performed in Stata v.13.0 (StataCorp LP, College Station, TX) and R
software (version 3.3.3, Robert Gentleman and Ross Ihaka, Auckland, New Zealand). Data
were described using absolute and relative frequencies for categorical variables and median
and interquartile range for quantitative variables with non-normal distribution. Comparisons
of categorical variables among groups of patients infected by each ribotype were done using
chi-square or Fisher’s exact tests. Quantitative variables comparisons were done using
ANOVA or Kruskal-Wallis tests, depending on the homoscedasticity assumption.
To explore the relationship among categories of qualitative variables related to clinical char-
acteristics at the time of CDI suspicion, a multiple correspondence analysis (MCA) was per-
formed. The following variables were included: fever 38.5 oC, ileus, unconsciousness,
abdominal distention, multiorgan failure, other infections and death. Quantitative variables
were categorized to be included in the analysis. White blood cells (WBC) count was catego-
rized according to the guidelines of the American College of Gastroenterology for C. difficile
infection (non-severe: <15,000 cells/mm3, severe: 14,999–34,999 cells/mm3, complicated dis-
ease:>35,000 cells/mm3) (20); C-Protein Reactive levels were categorized as low risk (<9.9
mg/L) and high risk levels (>10 mg /L).
Results
Epidemiological and demographic data of patients carrying the dominant
C. difficile ribotypes 591, 106 and 002
Demographic and clinical data of patients with suspicion of CDI and carrying the ribotypes
591, 106 and 002 were compared with data from patients with suspicion of CDI and carrying
other ribotypes (a total of 34 different ribotypes were included in this group) (Table 1). No sig-
nificant differences were found with regard to age, gender, hospital service [internal medicine,
surgery, hematology, intensive care unit (ICU), special care unit (SCU), orthopedic or
nephrology], risk factors (older than 65 years, abdominal surgery, endoscopy, nasogastric
tube, steroids usage, gastric acid suppressants, proton pump inhibitors, dialysis or stay in ICU
before symptoms), laboratory data, clinical signs and symptoms (fever, abdominal distention,
ileus, hypotension, loss of consciousness, multiorgan failure and colitis), discharge, other
infections or previous usage of antibiotics, with the exception of macrolides usage, which was
more frequently significant in those patients carrying ribotype 591 (Table 1).
Of 50 patients with suspicion of CDI, 27 (54%) carried ribotype 591, 12 (24%) ribotype 106
and 11 (22%) ribotype 002. After classification of patients as CDI or non-CDI according to the
free C. difficile A/B toxin in stool samples, it was found that 20 (74%) isolates of ribotype 591, 9
(75%) of ribotype 106 and 5 (45.5%) of ribotype 002 were recovered from CDI patients.
Regarding the ribotype 591, 13 (48.1%) isolates were from hospital A, 12 (44.5%) from hospital
B, and two (7.4%) from hospital C; 50% of the isolates ribotype 106 were from hospital A, and
the other 50% from hospital B; eight (72.7%) isolates corresponding to ribotype 002 were from
hospital A, 2 (18.2%) from hospital B and only one (9.1%) from hospital C.
An epidemic curve for the distribution of all ribotypes during the different periods of time
in the three hospitals revealed no trend in the number of cases diagnosed per month.
The MCA showed that the first two dimensions explained 45.6% of total variation. The vari-
ables with higher significant contribution to both dimensions were multiorgan failure,
Subtyping C. difficile Colombian isolates by MLVA
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Table 1. Demographic and clinical characteristics of patients carrying the 591, 106, 002 and other ribotypes.
Ribotype 591 Ribotype 106 Ribotype 002 Other ribotypes P value
n (%) n (%) n (%) n (%)
Total = 27 Total = 12 Total = 11 Total = 91
Male 15 (55.6) 4 (33.3) 5 (45.5) 49 (53.8) 0.548†
Female 12 (44.4) 8 (66.7) 6 (54.5) 42 (46.2)
Age
Median 65 66 65 61 0.614†
IQR 49–81 23–79 47–76 45–75
Hospital service
Internal medicine 18 (66.7) 8 (66.7) 8 (72.7) 64 (70.3) 0.972†
Surgery 5 (18.5) 2 (16.7) 0 18 (19.8) 0.510#
Hematology 2 (7.4) 1 (8.3) 0 3 (3.3) 0.482#
ICU 4 (14.8) 2 (16.7) 2 (18.2) 13 (14.3) 0.930#
SCU 2 (7.4) 0 1 (9.1) 3 (3.3) 0.377#
Orthopedic 5 (18.5) 2 (16.7) 1 (9.1) 9 (9.9) 0.579#
Nephrology 2 (7.4) 1 (8.3) 1 (9.1) 9 (9.9) 1.000#
Risk factors
Older 65 years 13 (48.1) 6 (50.0) 5 (45.5) 39 (42.9) 0.942†
Abdominal surgery 5 (18.5) 1 (8.3) 1 (9.1) 19 (20.9) 0.756#
Previous endoscopy 4 (14.8) 2 (16.7) 0 23 (25.3) 0.213#
Nasogastric tube 6 (22.2) 2 (16.7) 1 (9.1) 23 (25.3) 0.776#
Steroids 8 (29.6) 4 (33.3) 3 (27.3) 24 (26.4) 0.950#
Gastric acid suppressants 8 (29.6) 1 (8.3) 3 (27.3) 28 (30.8) 0.467#
Proton pump inhibitors 24 (88.9) 11 (91.7) 9 (81.8) 69 (75.8) 0.336†
Dialysis 7 (25.9) 3 (25.0) 2 (18.2) 12 (13.2) 0.313#
Stay ICU before symptoms 11 (40.7) 4 (33.3) 1 (9.1) 21 (23.1) 0.157#
Laboratory Data
White blood cells
Median 11700 11015 11330 8770 0.008†
IQR 6510–16800 9100–14425 9510–20260 6900–17600
WBC severity scoring
WBC < 15.000 cell/mm3 19 (70.4) 10 (83.3) 8 (72.7) 63 (69.2)
WBC 15.000–34.999 cells/mm3 6 (22.2) 1 (8.3) 1 (9.1) 27 (29.7) 0.047†
WBC 35.000 cell/mm3 2 (7.4) 1 (8.3) 2 (18.9) 1 (1.1)
C-Reactive protein
Median 7.86 8.35 9.96 9.14 0.036†
IQR 3.41–12.8 2.13–10.7 4.06–18.3 3.06–18.0 0.008†
Clinical signs and symptoms
Fever 6 (22.2) 3 (25) 1 (9.1) 14 (15.4) 0.616#
Abdominal distention 5 (18.5) 3 (25) 2 (18.2) 26 (28.6) 0.603#
Ileus 4 (14.8) 0 0 2 (2.2) 0.707#
Hypotension 3 (11.1) 1 (8.3) 1 (9.1) 9 (9.9) 0.954#
Loss of consciousness 3 (11.1) 0 0 2 (2.2) 0.157#
Multiorgan failure 1 (3.7) 0 0 4 (4.4) 0.365#
Colitis by tomography 2 (7.4) 0 0 4 (4.4) 0.697#
Discharge
Death 5 (18.5) 2 (16.7) 1 (9.1) 17 (18.7) 0.856#
Improve symptoms 21 (77.8) 10 (83.3) 10 (90.9) 73 (80.2)
(Continued)
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followed by death, hypotension, WBC35,000 cells/mm3, ileus, abdominal distention and
unconsciousness (Fig 1). Of note, ribotype 591 was related to abdominal pain and abdominal
distention.
Table 1. (Continued)
Ribotype 591 Ribotype 106 Ribotype 002 Other ribotypes P value
n (%) n (%) n (%) n (%)
Total = 27 Total = 12 Total = 11 Total = 91
Other infections 14 (51.9) 6 (50.0) 5 (45.4) 54 (59.3) 0.736†
Previous usage of antibiotics
Carbapenems 13 (48.1) 4 (33.3) 2 (18.2) 29 (31.9) 0.309#
Cephalosporins
3rd generation 4 (14.8) 1 (8.3) 2 (18.2) 12 (13.2) 0.912†
4th generation 2 (7.4) 2 (16.7) 1 (9.1) 10 (10.9) 0.840#
Macrolides 7 (25.9) 0 1 (9.1) 5 (5.5) 0.014#
Metronidazole 3 (11.1) 2 (16.7) 2 (18.2) 11 (12.1) 0.820#
CDI, Clostridium difficile infection; ICU, intensive care unit; SCU, special care unit.
According to severity scoring system of Guidelines for diagnosis, treatment and prevention of Clostridium difficile infections.
One patient carrying the ribotype 591 was transferred to a different hospital
Primary bacteremia, urinary tract infection, pneumonia.
# Fisher’s exact test
† Chi-square’s test
https://doi.org/10.1371/journal.pone.0195694.t001
Fig 1. Multiple correspondence analyses. Variable categories contributing to dimension 1 (x-axis) and dimension 2
(y axis); variables with major contribution are close to the cero line in the chart. Ten variables contributing to both
dimensions are shown.
https://doi.org/10.1371/journal.pone.0195694.g001
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Molecular and phenotypical characteristics of C. difficile ribotypes 591, 106
and 002
From the 27 isolates belonging to ribotype 591, 25 (92.6%) were positive for both PaLoc genes
(tcdA+/tcdB+) and the remaining 2 (7.4%) were positive only for the gene coding for toxin B
(tcdA-/tcdB+); of note, 92.6% of these isolates were positive for toxin production in cell culture
(Fig 2). From the 12 isolates belonging to ribotype 106, 6 (50%) harbored the tcdA+/tcdB+
genes, the remaining 6 (53.8%) isolates were tcdA-/tcdB+, and 11 (84.6%) isolates were positive
for toxin in cell culture (Fig 3). In connection with the ribotype 002, all isolates harbored the
PaLoc genes and were positive for toxin in cell culture (Fig 4).
Regarding the susceptibility of C. difficile to antibiotics, all isolates corresponding to 591,
106 and 002 ribotypes were susceptible to vancomycin and metronidazole, 75% to 100% were
resistant to clindamycin, and less than 15% of ribotypes 591 and 106 were resistant to moxi-
floxacina (Table 2). The breakpoints of MICs are shown for each isolate (Figs 2, 3 and 4).
MLVA subtyping
MLVA was performed on the C. difficile strains from the three predominant ribotypes. In the
present study, a total of 4 clonal complexes were identified for ribotype 591 (Fig 2) and two
clonal complexes for ribotype 002 (Fig 4) as defined by a STRD 2. Of interest, six isolates
coming from hospital B and belonging to ribotype 591 and a specific clonal complex with a
STRD 2 were distributed as follows: isolates S6 and S7 were isolated on an interval of five
days on October of 2013, isolates S11 and S14 were isolated on an interval of seven days
between November and December of 2013, and isolates S54 and S58 were isolated on an inter-
val of eight days on December of 2014 (Fig 2). In a similar fashion, three isolates belonging to
ribotype 002 (isolates L7, L8 and L9) with a STRD 2 and coming from hospital A were iso-
lated on an interval of eight days (Fig 4). Importantly, all isolates from the same clonal complex
were recovered from inpatients in different wards. For ribotype 106, none of the isolates
belonged to a cluster or clonal complex with a STRD > 10 (Fig 3).
Of note, in 22 (81.5%) of the isolates ribotype 591 locus A6 did not amplify; in addition,
locus C6 and E7 did not amplify in one isolate (Fig 2). A great diversity in the number of repe-
titions was noted especially for locus A6, B7 and C6, whereas locus E7, F3, G8 and H9 were the
most constant and common among all three ribotypes analyzed (Figs 2, 3 and 4).
Discussion
We previously reported that C. difficile ribotypes 591, 106 and 002 are the dominant strains cir-
culating in Colombia [11]. Although PCR-ribotyping is considered the gold standard method
for C. difficile typing and is the most employed for global analysis of related strains [12–14],
this technique has a lower discriminatory power, and alone is insufficient to investigate cases
of cross infection or epidemic outbreaks [15,16]. Subsequently, the MLVA technique was used
since it has been widely used to subtype C. difficile strains [17,19,27]. Although whole genome
sequencing has the higher discriminatory power than MLVA, Eyre et al. suggested that MLVA
provides similar discrimination power, and the effective implementing of WGS has several
barriers that need to be addressed [26]. MLVA was performed on 50 isolates of C. difficile
belonging to the ribotypes 591, 106 and 002. Amplification was obtained for the loci A6, B7,
C6, E7, F3, G8 and H9 as previously described. Of note, 81.5% of isolates belonging to ribotype
591 did not amplify the locus A6. This finding is in line with a previous study in which 33
strains of PCR ribotypes 023, 017, 078 and 126 did no amplify the locus A6 [28]; moreover,
absence of amplification has been already reported, and it was explained by the absence of this
Subtyping C. difficile Colombian isolates by MLVA
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locus in ribotype 078, as evidenced by sequence analysis [19,29,30]. Although in the present
study no sequence analysis was performed, absence of this locus should not be ruled out. Addi-
tionally, we observed a great diversity in the number of repetitions in the locus A6, B7 and C6,
results that are in accordance with other studies [15,28]. Thus, the diversity in the number of
repetitions observed may be due to an intraspecimen variation within the host as a conse-
quence of a rapid evolution of the microorganism.
MLVA results indicated that not all 27 isolates belonging to the ribotype 591 were closely
related at the clonal level, since they showed different STRDs values; only four different clonal
Fig 2. Analysis of ribotype 591 by MLVA. MLVA was applied to 27 isolates belonging to the ribotype 591.
Dendrogram showing similarities of banding patterns generated with high-resolution capillary gel-based
electrophoresis (CE)-PCR. MLVA clusters are identified by minimum-spanning tree: one clonal complex is defined by
a MLVA type with less than a two-locus difference. In addition, free fecal toxin A/B (FFT), toxin in cell culture (TC),
presence of PaLoc genes (tcdA/tcdB), minimal inhibitory concentrations (MIC) for vancomycin (VAN), metronidazole
(MTZ), moxifloxacin (MOX) and clindamycin (CLIN) are shown for each isolate with the respective breakpoints.
VNTR, variable-number tandem repeat.
https://doi.org/10.1371/journal.pone.0195694.g002
Fig 3. Analysis of ribotype 106 by MLVA. MLVA was applied to 12 isolates belonging to the ribotype 106.
Dendrogram showing similarities of banding patterns generated with high-resolution capillary gel-based
electrophoresis (CE)-PCR. MLVA clusters are identified by minimum-spanning tree: one clonal complex is defined by
MLVA type with less than a two-locus difference. In addition, free fecal toxin A/B (FFT), toxin in cell culture (TC),
presence of PaLoc genes (tcdA/tcdB), minimal inhibitory concentrations (MIC) for vancomycin (VAN), metronidazole
(MTZ), moxifloxacin (MOX) and clindamycin (CLIN) are shown for each isolate with the respective breakpoints.
VNTR, variable-number tandem repeat.
https://doi.org/10.1371/journal.pone.0195694.g003
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complexes with a STRD 2 were observed for this major ribotype. Regarding the ribotype
002, only two different clonal complexes with a STRD 2 were observed. None of the isolates
belonging to ribotype 106 showed a cluster or clonal complex distribution even with a
STRD < 10. Interestingly, six ribotype 591 isolates were shown to belong to three clonal com-
plexes with a STRD 2, they came from hospital B and were isolated from six patients in
three different time intervals; similarly, three isolates with the same ribotype 002 with a
STRD < 2 and coming from hospital A were isolated from three patients over an interval of 8
days; however, all isolates were recovered from inpatients in different wards. Thus, contamina-
tions of hospital environments due to persistence of spores or bacterial spread through asymp-
tomatic carriers have been suggested as important risk factors for healthcare-associated
infections [31]. Although in the present study we were not able to confirm the presence of C.
difficile spores in the environment or transmission from health personnel to patients or vice
versa, our findings clearly suggest a possible intra-hospital transmission within hospitals A and
B due to of ribotypes 002 and 591.
Interestingly, our results clearly indicate a difference in diversity and epidemiology of C. dif-
ficile when compared with those studies carried out in Europe and United States, where the
dominant C. difficile circulating strains were ribotypes 027, 001/072, 014/002 and 176
[1,32,33]. Regarding the demographic and clinical data of patients carrying ribotypes 591, 106
and 002, no significant differences were observed in any of the variables analyzed when these
dominant ribotypes were compared with the others detected, and when comparing between
CDI and non-CDI patients. Of note, the exploratory results of the MCA indicated that isolates
Fig 4. Analysis of ribotype 002 by MLVA. MLVA was applied to 11 isolates belonging to the ribotype 002.
Dendrogram showing similarities of banding patterns generated with high-resolution capillary gel-based
electrophoresis (CE)-PCR. MLVA clusters are identified by minimum-spanning tree: one clonal complex is defined by
MLVA type with less than a two-locus difference. In addition, free fecal toxin A/B (FFT), toxin in cell culture (TC),
presence of PaLoc genes (tcdA/tcdB), minimal inhibitory concentrations (MIC) for vancomycin (VAN), metronidazole
(MTZ), moxifloxacin (MOX) and clindamycin (CLIN) are shown for each isolate with the respective breakpoints.
VNTR, variable-number tandem repeat.
https://doi.org/10.1371/journal.pone.0195694.g004
Table 2. Antibiotic resistance profile of C. difficile strains of ribotypes 591, 106 and 002.
Clostridium difficile ribotype
591 106 002
n = 27 (%R) n = 12 (%R) n = 11 (%R)
Antibiotic
Metronidazole 0 0 0
Vancomycin 0 0 0
Clindamycin 27 (100 9 (75) 9 (81.8)
Moxifloxacin 4 (14.8) 0 0
R: resistance
https://doi.org/10.1371/journal.pone.0195694.t002
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of ribotype 591 were related to important clinical variables, and associated with presence of
abdominal pain and abdominal distention. Nonetheless, further studies should be addressed
to confirm this relation given the small number of samples analyzed.
We observed that some stool samples, in which toxigenic strains were isolated, are negative
for C. difficile toxins; this could be a result of sensitivity to the diagnostic test (EIA) used. Due
to variations in the sensitivity and specificity of the various diagnostic tests for CDI, the Euro-
pean Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommends the use
of a two-step algorithm to optimize diagnosis [34]. The use of one single EIA test for diagnos-
ing CDI, in stool samples, was a limitation in our study; however, at the time of the study other
tests/technologies were not available in Colombia (e.g. nucleic acid amplification tests/
NAATs, glutamate dehydrogenase/GDH) [21]. In addition, the results observed could also be
attributed to uncontrolled conditions in the pre-analytical phase; for instance, delays in the
transport of some samples to the laboratory could result in toxin degradation by host enzymes
[35,36]. Moreover, it would also be possible that some samples had very low level of toxin-pro-
ducing C. difficile strains at the time of sampling [36].
Interestingly, we found two strains that were tcdA-/tcdB+ with the same profile of toxins. A
possible explanation of these results may be that they can be attributed to different variants of
the PaLoc. The most common variant type is tcdA-negative, tcdB-positive (tcdA-/tcdB+).
Moreover, previous studies have reported deletions in the tcdA gene [37,38]; additionally, in
the present study the NK2/NK3 primers did not amplify this gene in these variant-type strains.
Furthermore, discordance between the negative cytotoxicity assay and the isolation of toxi-
genic ribotypes may be due to mixed C. difficile populations that could be present in the same
patient’s sample. According to this, toxin-negative colonies within a toxin-positive mixed pop-
ulation might have been selected for the toxicity assay.
There was no reduced susceptibility to vancomycin and metronidazole for any of the
ribotypes analyzed. In contrast, in a previous study reported that ribotypes 027 and 001/072
as well as the ribotype 106 showed an elevated MIC to metronidazole [39]. Similarly, it was
reported that ribotype 002 isolated from a Sweden patient who underwent long-term IV
vancomycin therapy showed resistant to this antibiotic with MICs between 4–8 mg/L over a
period of two years [40]. Moreover, the susceptibility to vancomycin and metronidazole
observed in the isolates analyzed in the present study could reflect the low frequency of
hypervirulent strains, at the time of sampling, which are more resistant to both antibiotics.
The current guidelines for CDI management recommend both of these antibiotics as the
first choice for treatment [34]. These results suggest to clinicians the advantage of adhering
to the international guidelines in our setting, since these antibiotics are effective for the
treatment of C. difficile infection.
Overall, the results obtained in the present study reinforce observations that MLVA is a
useful technique that is able to differentiate strains, even in C. difficile isolates belonging to
a same ribotype. Nonetheless, the variations observed, using this technique, in some iso-
lates from a specific ribotype depend on which isolates are picked from the primary culture,
as described elsewhere [28]. This dependence could affect epidemiological links among the
strains analyzed, even though, an intra-hospital transmission of ribotypes 591 and 002 is
presumed in hospitals B and A, respectively. No epidemiological association on time and
space after analyzing the C. difficile clusters was detected, demonstrating the high molecu-
lar heterogeneity of strains circulating in Colombia. In addition, our results showed that
patients infected by the dominant ribotypes 591, 106 and 002 have similar clinical
characteristics.
Subtyping C. difficile Colombian isolates by MLVA
PLOS ONE | https://doi.org/10.1371/journal.pone.0195694 April 12, 2018 10 / 14
Conclusions
This study confirmed that MLVA is a useful discriminatory technique, and allowed us to iden-
tify a possible intra-hospital transmission of C. difficile ribotypes; this technique could be effec-
tive at tracing and tracking the source of contamination and is implementation could aid
surveillance programs. Further research is needed to understand the clonal spread and long-
term epidemiology of ribotypes 591, 106 and 002 as the predominant clones circulating in
Colombia; in addition, a combination of two or more methods are desirable to provide essen-
tial information for investigating C. difficile population and clonal emergence.
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